EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb
|
|
- Jasper Gibbs
- 5 years ago
- Views:
Transcription
1 EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb A. Medina Servicio de Cardiología Hospital Universitario de Gran Canaria Dr. Negrín Islas Canarias (Spain)
2 Provisional stenting has been proved to be the treatment of choice in most bifurcated coronary lesions. BVS: concern about the scaffold integrity with balloon intervention (balloon diameter mm). Our own in vitro test shows integrity of BVS (1 or 2 balloon and low pressure inflation).
3 Provisional BVS implantation Lesion located in a major bifurcation point MB 2.5 mm in diameter SB 2.25 mm in diameter SB lesion length < 10 mm 99 bifurcated coronary lesions SBA + B0 B0 B1 B2 B3 n = 12 n = 41 n = 10 n = 29 n = 1 Kissing Balloon 26 DES in the SB Two stent (elective inverted T) SMS 3 n = 6
4 B2 BVS + KB KISSING BALLOON (8 atm) 3.5 x 28 mm BVS (16 atm) FGBody temperature Facilitates SB access? 1 2 S I D E 2.5 x 15 mm (8 atm) M A I N B R A N C H F I R S T n = 8 BVS 3.5 mm (3 & 2.5 mm) Mild waist in second balloon V E S S E L F I R S T Optimal geometry of MV scaffolding 3.5 x 28 mm BVS after KB (3-2.5) 3 x 25 mm (8 atm) Mild waist in second balloon n = 5 BVS 3 mm (2.5 & 2.5 mm)
5 A paradox : Kissing balloon Larger maximum diameter and less crown stretching 3.5 mm BVS overexpanded Eccentric Concentric crown link ondulated non ondulated Kissing Oversizing 3 mm 5.5 mm 4.5 mm 4.5 mm BVS integrity 2.5 mm BVS fracture Area mm 2 Area mm 2
6 Predilation (direct BVS failed) #39# {1,1,1} 3.5 x 18 mm BVS SB 1 st MV 1 st 1 2 MV 2 nd SB 2 nd LAD 3 mm Dg 2.5 mm (8 atm) After KB inflation
7 BASELINE Dg Measurements taken before SB origin LAD MLA 3.42 mm 2 AFTER BVS BVS 3.5 mm 14 atm Dg LAD CORONARY VESSEL WALL CONTROLS EXPANSION OF BVS BVS 3.5 mm 14 atm CSA 8.75 mm 2 KB 3 & 2.5 mm 8 atm Dg CSA 9.64 mm mm 2 Area < recommended limit wire LAD KB 3 & 2.5 mm 8 atm 3.5 mm BVS: 100% expansion = 9.6 mm 2 4 mm balloon = mm 2 AFTER BVS
8 BVS & Kissing A) Balloons selection: - MB balloon 0.5 mm less than BVS diameter - SB balloon 2.5 mm BVS diameter MB balloon SB balloon 3.5 mm 3 mm 2.5 mm 3 mm 2.5 mm 2.5 mm B) Balloons inflation pressure 8 atm
9 Clinical data n=26 Age, years 59 ± 12 Male gender 22 (85) Hypertension 12 (48) Diabetes mellitus 6 (23) Hypercholesterolemia 12 (48) Current smoking 15 (60) Unstable 22 (85) Multivessel disease 8 (30) Baseline angiographic data n=26 Location of the lesion, n (%) LAD-Dg LCx-Cx RCA Type of lesion, n (%) {1,1,1} {1,1,0} {1,0,1} {0,1,1} {1,0,0} {0,1,0} {0,0,1} 17 (65) 6 (23) 3 (12) 11 (42) 6 (23) 0 (0) 5 (19) 2 (8) 2 (8) 0 (0) QCA Main vessel Side branch Lesion length, mm 21.9 ± ± 2.1 {_,_,1} 16 (61%) Left ventricular EF 63 ± 13 Data are expresed as n (%) Prox. reference diameter 2.97 ± 0.37 Distal reference diameter 2.53 ± ± 0.3 MLD, mm 1.13 ± ± 0.41 DS,% 62 ± ± 16 *BVS diameter was selected according to proximal vessel diameter
10 Baseline QCU (n =26) Baseline Dg Proximal Before SB origin After SB origin Distal MLA LAD 8,74 mm 2 2,14 mm 2 2,47 mm 2 3,96 mm 2 Main branch SB Proximal Before SB origin MLA After SB origin Distal Ostium EEL, mm ± ± ± ± ± ± 2.8 Mean diameter,mm 3.20 ± ± Lumen area, mm ± ± ± ± ± ± 1.8 Plaque area, mm ± ± ± ± ± ± 1.1 Plaque burden, % 44 ± ± ± ± ± ± 15 MLA location, n 4 (16%) 3 (12%) (46%) 2 (8%) 5 (25%) Eccentric (MLA), n (40%) *BVS diameter was selected according to proximal main branch diameter
11 After BVS implantation Area 4.67 mm2 MeanD 2.43 mm Min 2.20 Max 2.68 Area 5.23 mm2 MeanD 2.57 mm Min 2.39 Max 2.93 After SB origin Before SB origin LAD D Dg P After Kissing Δ 1.29 mm 2 Area 4.55 mm2 MeanD 2.40 mm Min 2.15 Max 2.63 Area 6.52 mm2 MeanD 2.87 mm Min 2.60 Max 3.18 LAD D Dg P
12 Procedural data BVS 2.5 mm n= 4 BVS 3 mm n= 9 BVS 3.5 mm n= 13 KB n = 26 KB n = 26 IVUS guidance, n 26 (100%) Direct BVS implantation, n 16 (62%) MB predilation after failure, n 6 (23%) Elective MB predilation, n 4 (15%) MB balloon diameter, mm 2.44 ± 0.16 MB balloon length, mm 17.7 ± 2.6 MB balloon pressure, atm 8.4 ± 2 BVS diameter, mm 3.16 ± 0.37 BVS length, mm 24 ± 8 BVS inflation pressure, atm 15.9 ± 1.9 BVS inflation time, s 72 ± 16 KISSING BALLOON DATA MB balloon diameter, mm 2.76 ± 0.30 MB balloon length, mm 16.6 ± 2.9 MB balloon pressure, atm 7.6 ± 0.9 SB balloon diameter, mm 2.39 ± 0.25 SB balloon length, mm 16 ± 3 SB balloon pressure, atm 7.7 ± 1.2
13 Changes in BVS geometry after kissing balloon Dg LAD LAD Before KB After KB p PROXIMAL BVS SEGMENT Area, mm ± ± BEFORE SB ORIGIN Area, mm 2 SI 6.70 ± ± ns AFTER SB ORIGIN Area, mm ± 1.76 SI ± ns DISTAL BVS SEGMENT Area, mm ± ± SI (BVS symmetry index) Nominal BVS expansion Maximum tolerated expansion 3 mm Ø = 7.1 mm 2 (3.5 mm Ø = 9.6 mm 2 ) 3.5 mm Ø = 9.6 mm 2 (4 mm Ø = mm 2 )
14 Major adverse cardiac events and follow-up results (KB) Primary success (one patient needed SB stenting) 100% IN HOSPITAL KB n=26 Non-Q-wave MI 1 (4%)* Death 0 Sub-acute BVS thrombosis (PAMI) 1 (4%) FOLLOW-UP (7 ± 3 months) Recurrent infarction 0 Death (all causes) 0 Need of TLR 0 BVS thrombosis 0 Total MACE 2 (8%) * troponin elevation within 48 h post-procedure of 5 ULN with either symptoms of myocardial ischemia, new ischemic ECG changes, or documented complications during the procedure Angio-CT was performed at follow-up (n = 25). No restenosis
15 T stenting after kissing: BVS (MB) & DES (SB) #97# {0,1,1} DES BVS 3 x 18 mm BVS KB inflation 2.25 x 18 mm DES
16 Conclusions Kissing balloon for bifurcated coronary lesions treated with BVS seems to be safe and feasible Kissing balloons inflation ( 8 atm) Kissing balloons selection - MB 0.5 mm less than BVS diameter - SB 2.5 mm Mid-term clinical & angio CT follow up encouraging. IVUS or OCT guidance should be used more frequently than with metallic stent. 2-3 YEARS FOLLOW-UP WILL PROVIDE A MORE DEFINITIVE ANSWER
LM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationBifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
More informationFFR-guided Jailed Side Branch Intervention
FFR-guided Jailed Side Branch Intervention - Pressure wire in Bifurcation lesions - Bon-Kwon Koo, MD, PhD Seoul National University Hospital, Seoul, Korea Bifurcation Lesions Bifurcation Lesions Still
More informationSTENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationInsight from the CACTUS trial Coronary Bifurcation Application of the Crush
EBC - Prague 26-28 september 2008 Insight from the CACTUS trial The role of final kissing balloon inflation F. Airoldi,, A. Colombo San Raffaele Scientific Institute EMO Centro Cuore,, Columbus Hospital
More informationSide Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
More informationSeptember Peter Barlis. Royal Brompton Hospital, London, UK
3rd EBC Meeting European Bifurcation Club September 2007 PALAU DE LA MUSICA, SalaRodrigo VALENCIA, SPAIN Culotte Technique in Left Main Disease Peter Barlis Carlo DiMario Royal Brompton Hospital, London,
More informationWhy I try to avoid side branch dilatation
Why I try to avoid side branch dilatation Hyeon-Cheol Gwon Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Why I don t kiss? I kiss! I prefer to discuss SB ballooning rather
More informationΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ
ΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ DR ΝΙΚΟΛΑΟΣ ΚΑΥΚΑΣ MD, FESC Διευθυντής, Υπεύθυνος Αιμοδ/κού Εργαστηρίου Καρδιολογική Κλινική Γεν. Νοσοκομείο ΚΑΤ-ΕΚΑ PCI in Coronary Bifurcations Bifurcations
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationIVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.
Left Main and Bifurcation Summit IVUS-Guided d Provisional i Stenting: ti Plaque or Carina Shift Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan College of Medicine Asan Medical Center,
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationProtection of side branch is essential in treating bifurcation lesions: overview
Angioplasty Summit TCT Asia Pacific Seoul, April 26-28, 2006 Protection of side branch is essential in treating bifurcation lesions: overview Alfredo R Galassi, MD, FACC, FSCAI, FESC Head of the Catetherization
More informationFinal Kissing Ballooning Returns? The analysis of COBIS II registry
Final Kissing Ballooning Returns? The analysis of COBIS II registry Hyeon- Cheol Gwon Heart Vascular & Stroke Ins?tute, Samsung Medical Center Sungkyunkwan University School of Medicine Final Kissing Ballooning
More informationContemporary therapy of bifurcation lesions
Contemporary therapy of bifurcation lesions Dr Angela Hoye MB ChB PhD MRCP Interventional Cardiologist Kingston-upon-Hull, UK Hull The challenge of bifurcations Risk of peri-procedural infarction Relatively
More informationLe# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
More informationDr Aniket Puri. OCT guided BVS for LMCA to LAD : Optimising the 'Pot'
OCT guided BVS for LMCA to LAD : Optimising the 'Pot' Dr Aniket Puri MD,DM,FRACP, FACC, FSCAI, FAPSIC Consultant Interventional Cardiologist Christchurch Hospital and Canterbury DHB(Univ of Otago) Christchurch,New
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationPost PCI functional testing and imaging: case based lessons from FFR React
Post PCI functional testing and imaging: case based lessons from FFR React Joost Daemen, MD, PhD, FESC Optics in Cardiology 2018 April 21st, 2018 10.15 10.30h Disclosure Statement of Financial Interest
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationA Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations
Innovative Devices : Non Stent Technologies : Drug Eluting Balloons A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations Pieter R. Stella, MD Director CardioVascular Research
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More information6 th European Bifurcation Club October BUDAPEST. Kissing in simple strategy? Why and how I kiss. Y. Louvard, ICPS, Massy France
6 th European Bifurcation Club 22-23 October 2010 - BUDAPEST Kissing in simple strategy? Why and how I kiss Y. Louvard, ICPS, Massy France A long experience of kissing 1996 Patients 79 Final Kissing balloon
More informationI have nothing to disclose.
I have nothing to disclose. ESC congress of cardiology, 25-29th August 2012, Munich, Germany Minsk-Village 6, August 26 th, 2:22 PM Session: The grey zone of coronary interventions: The real bifurcation
More informationWelcome to the 8 th European Bifurcation Club October Barcelona
Welcome to the 8 th European Bifurcation Club 12-13 October 2012 - Barcelona Safety and clinical efficacy of Sideguard stent for treatment of bifurcation lesions Interim results from European multicentre
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationManagement of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI
Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent Masahiko Ochiai MD, FACC, FESC, FSCAI Division of Cardiology and Cardiovascular Surgery Showa University Northern Yokohama Hospital
More informationBifurcation Stenting: IVUS and OCT Information
Bifurcation Stenting: IVUS and OCT Information Yoshinobu Murasato MD, PhD (New Yukuhashi Hospital) On behalf of J-REVERSE investigators October 14-15, 2011, Lisbon Proximal stent deformation induced by
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationBetween Coronary Angiography and Fractional Flow Reserve
Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve Seung-Jung Park, MD., PhD. University of Ulsan, College of Medicine Asan Medical Center, Seoul, Korea Visual - Functional
More informationComplex PCI of an LAD/Diagonal bifurcation lesion (Medina 1,1,1) utilizing the DK Crush technique ".
Complex PCI of an LAD/Diagonal bifurcation lesion (Medina 1,1,1) utilizing the DK Crush technique ". "Σύμπλοκη αγγειοπλαστική βλάβης διχασμού LAD/Diagonal (Medina 1,1,1) με την τεχνική DK crush ". Anastasios
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the Everolimus Eluting Stent Bernard Chevalier
More informationThe Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections. Martin B. Leon, MD
The Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New York City Angioplasty
More informationPlaque Shift vs. Carina Shift Prevalence and Implication
TCTAP 2013 Fellowship Course Left Main and Bifurcation PCI: Bifurcation PCI Plaque Shift vs. Carina Shift Prevalence and Implication Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan
More informationMid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
More informationIntegrated Use of IVUS and FFR for LM Stenting
Integrated Use of IVUS and FFR for LM Stenting Gary S. Mintz, MD Cardiovascular Research Foundation Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease Fisher
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationFFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT
FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT01724957 Dobrin Vassilev MD, PhD Assoc. Prof. in Cardiology Head Cardiology Clinic, Alexandrovska University Hospital Medical
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationMedtronic Symposium The Complex Bifurcation Patient: new insights into stent selection
Medtronic Symposium The Complex Bifurcation Patient: new insights into stent selection Carlo Trani, MD, FESC Cardiology Department, Catholic University of the Sacred Heart, Rome - Italy How would you treat
More informationFlexibility of the COMBO Dual Therapy Stent
TM CaseSpotlight Flexibility of the COMBO Dual Therapy Stent Doctor Peter den Heijer is an of the Catheterization Laboratory at the Department of Cardiology of the Amphia Ziekenhuis, Breda, The Netherlands.
More informationA Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience
A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research The Cardiovascular
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationThe Tryton Side Branch System in Distal Left Main PCI
The Tryton Side Branch System in Distal Left Main PCI Yaron Almagor, MD Director, Interventional Cardiology Shaare Zedek Medical Center Jerusalem, Israel TCTAP Seoul April 2013 Speaker s name: YARON ALMAGOR
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationSide branch occlusion in 500 ABSORB BVS
Side branch occlusion in 500 ABSORB BVS Clinical implications and Solutions Robert-Jan van Geuns, MD, PhD Associate Professor,Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands On behalf
More informationClinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD
Clinical Value of OCT Guidance for Coronary Stenting Giulio Guagliumi, MD 100 % Endovascular Imaging Indications of use 87.5 % 75 % 57.5 % 50 % 45 % 25 % 15 % 0 Lesion morphology Stent optimization Lesion
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationOCTOBER. OCT Optimised Bifurcation Event Reduction. A Nordic Baltic British clinical outcome trial
OCT Optimised Bifurcation Event Reduction A Nordic Baltic British clinical outcome trial NIELS RAMSING HOLM, Skejby Denmark Study start: OCTOBER 2016 OCTOBER LMCA or non-lmca bifurcations with SB 2.5mm
More informationY. Louvard, ICPS, Massy, France. TCT Asia Pacific 2010
Provisional Bifurcation Stenting: Main Branch First Y. Louvard, ICPS, Massy, France TCT Asia Pacific 2010 No conflict of interest to declare M Main prox. first A Main Accross side first D Distal first
More informationMULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.
More informationWhat Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas
What Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas Stent Era Lessons on Vessel Preparation Under expanded stent consequences Abrupt
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationPOLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis
POLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis Robert J. Gil 1,2, MD, PhD, FESC 1- Mossakowski Medical Research Centre, Polish Academy of Sciences 2- Invasive
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC Seoul, Korea: 25-27 27 April 2007 Session: Left mains & bifurcation intervention An integrated approach to bifurcation lesions: lessons from years of randomized
More informationPatrick W. Serruys Imperial College, London, UK Erasmus University MC, Rotterdam, the Netherlands
TCT 2014 13 Sep 2014-17 Sep 2014, Washington, DC - U.S.A Plenary Session XII : Late-Breaking clinical Trials #2 ABSORB II : A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold
More informationFFR and IVUS Guided DES Implantation in Long Diffuse Lesions
FFR and IVUS Guided DES Implantation in Long Diffuse Lesions Can We Reach Optimal DES Expansion With Conventional Stent Delivery System in Long Diffuse Lesion? Seung-Jea Tahk, MD., PhD. Ajou University
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationConsensus so far and what we will be focusiong on this time
Consensus so far and what we will be focusiong on this time The 6 th European Bifurcation Club Meeting Budapest October 22-23 2010 Jens Flensted Lassen, MD, PH.D., FESC. Department of Cardiology B Skejby
More informationBiodegradable Stents An update and work-in
Biodegradable Stents An update and work-in in-progress Department of Cardiology, Hideo Tamai, M.D. Metallic stents... Background induce a varing degree of thrombogenesis eg, subacute thrombosis in complex
More informationUpdate from the Tryton IDE study
Update from the Tryton IDE study Maciej Lesiak EBC 2015 - Athens The Tryton Bifurcation Trial: A randomized comparison of a provisional one-stent vs. a dedicated two-stent strategy for true bifurcation
More informationDr. Robert J. van Geuns. Thoraxcenter ErasmusMC Rotterdam On behalf of Dr. Jean Fajadet and Co-investigators
Complex coronary bifurcation lesions treated with the novel polymer-free dedicated bifurcation paclitaxel-eluting stent (Nile pax): clinical and angiographic results of the prospective, multicenter bipax
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationLessons for technique and stent choice
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Session: What are the requirements for using a stent in a bifurcation? Lessons for technique and stent choice October 12 th : 16:45 17:50 Goran
More informationThe 3 top Messages from technique Specific problems Solving
The 3 top Messages from technique Specific problems Solving Alaide Chieffo Interventional Cardiology Unit San Raffaele Hospital Milan - Italy PROBLEMS DURING PROVISIONAL: SB PROTECTION AND RESCUE Francesco
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationCurrent DES designs and expansion capacity testing
construction of Sagrada Família basilica had commenced in 1882 anticipated completion date: 2026 Current DES designs and expansion capacity testing N. FOIN, MSc, PhD INTERNATIONAL CENTRE FOR CIRCULATORY
More informationBasics of Angiographic Interpretation Analysis of Angiography
Basics of Angiographic Interpretation Analysis of Angiography Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Seoul, Korea What made us nervous Supervisors Stent Contrast
More informationBifurcation Stenting. European Bifurcation Club update. Ioannis Iakovou, MD Onassis Cardiac Surgery Center Athens, Greece
Bifurcation Stenting. European Bifurcation Club update. Ioannis Iakovou, MD Onassis Cardiac Surgery Center Athens, Greece The not so new development One vs. two stents General consensus In most bifurcational
More informationEBC Rules of Bifurcation PCI
EBC Rules of Bifurcation PCI Y. Louvard, ICPS, Massy, France What is a coronary bifurcation? «Murray s law» Bifurcation branching laws D1 Murray s law D 3* 3* 3* 1 = D 2 + D 3 D3 Finet s law D 1 = 0.67(D
More informationFFR Fundamentals and Measurements
FFR Fundamentals and Measurements Ghassan S. Kassab Thomas Linnemeier Chair Professor Biomedical Engineering, Indiana University Purdue University Indianapolis Principle of FFR Q S ( P P ) / R P max d
More informationREFCTRI/2010/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Mon, 23 Apr 2018 20:30:46 GMT) CTRI Number CTRI/2010/091/000460 [Registered on: 15/10/2010] - Last Modified On 17/04/2012 Post Graduate Thesis Type of Trial
More informationInsight from Nordic III
Insight from Nordic III Fifth European Bifurcation Club Meeting Berlin 16-17 October 2009 Jens Flensted Lassen, MD, PH.D., FESC. Department of Cardiology Skejby Hospital, University of Aarhus Denmark Nordic-Baltic
More informationDISAPPEARING STENT: IS THE TIME APPEARED?
DISAPPEARING STENT: IS THE TIME APPEARED? Carlo Cernetti Chief Cardiology Division San Giacomo Hospital Castelfranco Veneto (TV) 1 THE BEGINNING START randomized study (n=452) Long-term follow-up The benefit
More informationReZolve2 Bioresorbable Coronary Scaffold Clinical Program Update
ReZolve2 Bioresorbable Coronary Scaffold Clinical Program Update Dr. David Muller St Vincent s Hospital Sydney, Australia 0 Potential conflicts of interest Speaker's name: Dr. David Muller I do not have
More informationComplex Coronary Interventions: Bifurcations. John M. Lasala MD PhD Professor of Medicine Washington University St Louis, Missouri
Complex Coronary Interventions: Bifurcations John M. Lasala MD PhD Professor of Medicine Washington University St Louis, Missouri Disclosures Advisory Board Boston Scientific, St. Jude Medical Speaker-
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationDK Crush,Culotte,SKS,T or TAP. Subhash Chandra, MD,DM,FACC Chairman,Cardiac Sciences BLK Super Speciality Hospital, Pusa Road, New Delhi
PCI for Bifurcations: Which is the best strategy DK Crush,Culotte,SKS,T or TAP Subhash Chandra, MD,DM,FACC Chairman,Cardiac Sciences BLK Super Speciality Hospital, Pusa Road, New Delhi CSI 2018 Selection
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationPCI for Ostial Lesion
PCI for Ostial Lesion ii) LAD ostial Osamu Katoh,M.D. kyoto Katsura Hospital Cardiovascular Center PCI for a LAD ostial lesion is well-known to be associated with a high restenosis rate because of excessive
More informationBifurcations Bad Krozingen I
Bifurcations Bad Krozingen I Clinical outcome 5 years after routine T-Stenting versus provisional T-stenting in the treatment of de novo coronary bifurcation lesions using sirolimus-eluting stents M. Ferenc
More informationThe Nordic Bifurcation Stent Technique Study. A Randomized trial of CRUSH vs CULOTTE Stenting
The Nordic Bifurcation Stent Technique Study A Randomized trial of CRUSH vs CULOTTE Stenting Pål Gunnes, Matti Niemela, Kari Kervinen, Andrejs Erglis, Indulis Kumsars, Jens F Lassen, Michael Mæng, Jan
More informationAnatomical, physiological and clinical relevance of a side branch
Anatomical, physiological and clinical relevance of a side branch : Which branch really needs a stent? Bon-Kwon Koo, MD, PhD, Seoul, Korea Bifurcation lesion: The GREAT EQUALIZER! No intervention = Balloon
More informationIntervention: How and to which extent is technology helping us?
Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction
More informationBioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland Disclosures I am not Ron Waksman 1 Clinical experience with AMS
More informationNew Double Stent Technique
New Double Stent Technique Jasvindar Singh MD, FACC Associate Professor of Medicine Barnes-Jewish Hospital/Washington University in St. Louis jzsingh@dom.wustl.edu New Double Stent Technique Jasvindar
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationFFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results. Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria
FFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria I would like to express my personal gratitude to Dr. BK Koo for opening
More informationIVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation
IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation SURE Trial: Restenosis in non-stented lesions Average of the two image slices with the smallest
More informationIVUS vs FFR Debate: IVUS-Guided PCI
IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement
More informationInsights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up
Insights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up Ron Waksman, MD FACC FSCAI FESC Professor of Medicine, Georgetown University Director, Cardiovascular Research
More informationPatient. Clinical data Indications: Operation date. Comorbidities: Patient code Birth date: / /
Patient Patient code Birth date: / / Sex: Male Height (cm): Female Weight (kg): Risk Factors: Family history of coronary disease: Hypertension Dyslipidemia Peripheral disease Diabetes Comorbidities: No
More information